The early-stage study showed that Viking Therapeutics’ oral obesity candidate VK2735, a dual agonist of the GLP-1 and GIP receptors, elicited a 3.3% reduction in mean body weight. The company plans to start a Phase II trial.
Tag Archive for: Viking Therapeutics
Viking Therapeutics announced Tuesday that its GLP-1/GIP receptor dual agonist helped patients lose up to nearly 15% of their weight over about three months in a Phase II study.
Viking Therapeutics Inc said on Tuesday its experimental drug met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease, sending its shares about 6% higher in early trade.
The drugmaker, which will begin a mid-stage trial for the drug in mid-2023, is entering the race to develop an obesity treatment, which has contenders including Altimmune, Novo Nordisk, and Eli Lilly.
